Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Change in Cash (2022 - 2025)

Historic Change in Cash for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • Zentalis Pharmaceuticals' Change in Cash fell 6566.43% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year increase of 9676.23%. This contributed to the annual value of $5.8 million for FY2024, which is 13878.61% up from last year.
  • Zentalis Pharmaceuticals' Change in Cash amounted to $1.5 million in Q3 2025, which was down 6566.43% from -$4.3 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' 5-year Change in Cash high stood at $230.3 million for Q2 2023, and its period low was -$155.8 million during Q3 2023.
  • Moreover, its 4-year median value for Change in Cash was -$640000.0 (2024), whereas its average is -$1.4 million.
  • The largest annual percentage gain for Zentalis Pharmaceuticals' Change in Cash in the last 5 years was 84655.54% (2023), contrasted with its biggest fall of 1605733.59% (2023).
  • Zentalis Pharmaceuticals' Change in Cash (Quarter) stood at $518000.0 in 2022, then crashed by 16057.34% to -$82.7 million in 2023, then soared by 91.02% to -$7.4 million in 2024, then skyrocketed by 119.85% to $1.5 million in 2025.
  • Its Change in Cash stands at $1.5 million for Q3 2025, versus -$4.3 million for Q2 2025 and $8.0 million for Q1 2025.